IMMX Latest Press Releases

-- January 28, 2026 --

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 Globe Newswire 8:45 AM

-- December 9, 2025 --

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Globe Newswire 5:45 PM

-- December 7, 2025 --

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Globe Newswire 6:20 PM

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis Globe Newswire 6:15 PM

-- November 12, 2025 --

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch Globe Newswire 8:45 AM

-- November 3, 2025 --

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 Globe Newswire 8:45 AM

-- October 14, 2025 --

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference Globe Newswire 8:45 AM

-- October 6, 2025 --

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting Globe Newswire 4:05 PM

-- October 1, 2025 --

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference Globe Newswire 8:45 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software